PortView
Invesco Pharmaceuticals (PJP) ETF Holdings & Analysis
ETFOther
What PJP does
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Fund profile
Top holdings
| Holding | Weight | |
|---|---|---|
| Amgen Inc | 5.75% | |
| Abbott Laboratories | 5.54% | |
| Merck & Co Inc | 5.52% | |
| AbbVie Inc | 5.38% | |
| Johnson & Johnson | 5.19% | |
| Gilead Sciences Inc | 4.94% | |
| Pfizer Inc | 4.87% | |
| Eli Lilly & Co | 4.80% | |
| Corcept Therapeutics Inc | 4.66% | |
| Travere Therapeutics Inc | 3.68% |
Sector allocation
| Healthcare | 100.00% |
Geographic allocation
| United States | 94.03% |
| Ireland | 5.93% |
| Other | 0.04% |
PortView Portfolio Insights
PortView analyzes how PJP fits your actual portfolio — position weight, ETF overlap with your other funds, sector and geographic exposure, concentration, and how this fund contributes to your portfolio risk and return. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze PJP in PortView →Related securities
Related stocks
Frequently asked questions
- What does PJP track?
- PJP is the Invesco Pharmaceuticals ETF, a Other ETF.
- What is the expense ratio of PJP?
- Expense ratio data for PJP is shown on the page when available from our data provider.
- What are the largest holdings in PJP?
- Top holdings include AMGN, ABT, MRK, ABBV, JNJ.
- How can PortView analyze PJP overlap with other ETFs?
- PortView computes the holdings overlap between PJP and the other ETFs and stocks you own, plus your combined sector and geographic exposure, so you can see true diversification.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.